Equity research - Bayer ag: the growth path for a pharma titan
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/140596 |
Resumo: | One of Bayer AG’s strongest assets and operational flagship across the globe has been its pharmaceutical division, which comprisesroughly40% of total sales of the group, as of 2020. However, it is now dealing with major business shifts which undermine its the medium-term growth prospects, as its two best-selling products, Xarelto TM and Eylea TM, are on the verge of a patent-cliff. As such, Bayer’s pharmaceutical division has been investing on a promising pipeline of medicines, some with the so-called ‘blockbuster’ potential, such as Nubeq a TM, Fineren oneTM and Elinzanetant TM, while it has too been acquiring independent research and development firms and building up external partnerships as to solidify its own footprint on the cell and gene therapy segment, which is expected to have a CAGR of above 25% and to reach US$48bn market value by 2026.But isn’t that an overly optimistic and linear path? In finding so, on this working paper, we describe some of Bayer and the industry’s main characteristics and challenges in the upcoming years, in light of a valuation model to estimate Bayer AG’s share price as of December 2022. |
id |
RCAP_bc7c619633ce708f24b9a352d86344c2 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/140596 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Equity research - Bayer ag: the growth path for a pharma titanValuationFinanceEquity researchPharmaceutical industryDcf valuationCrop scienceConsumer healthBayer agDomínio/Área Científica::Ciências Sociais::Economia e GestãoOne of Bayer AG’s strongest assets and operational flagship across the globe has been its pharmaceutical division, which comprisesroughly40% of total sales of the group, as of 2020. However, it is now dealing with major business shifts which undermine its the medium-term growth prospects, as its two best-selling products, Xarelto TM and Eylea TM, are on the verge of a patent-cliff. As such, Bayer’s pharmaceutical division has been investing on a promising pipeline of medicines, some with the so-called ‘blockbuster’ potential, such as Nubeq a TM, Fineren oneTM and Elinzanetant TM, while it has too been acquiring independent research and development firms and building up external partnerships as to solidify its own footprint on the cell and gene therapy segment, which is expected to have a CAGR of above 25% and to reach US$48bn market value by 2026.But isn’t that an overly optimistic and linear path? In finding so, on this working paper, we describe some of Bayer and the industry’s main characteristics and challenges in the upcoming years, in light of a valuation model to estimate Bayer AG’s share price as of December 2022.André, RosárioRUNSantos, Rui Miguel Pinto dos2022-06-23T16:34:22Z2022-01-132021-12-172022-01-13T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10362/140596TID:202972747enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:17:47Zoai:run.unl.pt:10362/140596Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:49:44.370508Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Equity research - Bayer ag: the growth path for a pharma titan |
title |
Equity research - Bayer ag: the growth path for a pharma titan |
spellingShingle |
Equity research - Bayer ag: the growth path for a pharma titan Santos, Rui Miguel Pinto dos Valuation Finance Equity research Pharmaceutical industry Dcf valuation Crop science Consumer health Bayer ag Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
title_short |
Equity research - Bayer ag: the growth path for a pharma titan |
title_full |
Equity research - Bayer ag: the growth path for a pharma titan |
title_fullStr |
Equity research - Bayer ag: the growth path for a pharma titan |
title_full_unstemmed |
Equity research - Bayer ag: the growth path for a pharma titan |
title_sort |
Equity research - Bayer ag: the growth path for a pharma titan |
author |
Santos, Rui Miguel Pinto dos |
author_facet |
Santos, Rui Miguel Pinto dos |
author_role |
author |
dc.contributor.none.fl_str_mv |
André, Rosário RUN |
dc.contributor.author.fl_str_mv |
Santos, Rui Miguel Pinto dos |
dc.subject.por.fl_str_mv |
Valuation Finance Equity research Pharmaceutical industry Dcf valuation Crop science Consumer health Bayer ag Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
topic |
Valuation Finance Equity research Pharmaceutical industry Dcf valuation Crop science Consumer health Bayer ag Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
description |
One of Bayer AG’s strongest assets and operational flagship across the globe has been its pharmaceutical division, which comprisesroughly40% of total sales of the group, as of 2020. However, it is now dealing with major business shifts which undermine its the medium-term growth prospects, as its two best-selling products, Xarelto TM and Eylea TM, are on the verge of a patent-cliff. As such, Bayer’s pharmaceutical division has been investing on a promising pipeline of medicines, some with the so-called ‘blockbuster’ potential, such as Nubeq a TM, Fineren oneTM and Elinzanetant TM, while it has too been acquiring independent research and development firms and building up external partnerships as to solidify its own footprint on the cell and gene therapy segment, which is expected to have a CAGR of above 25% and to reach US$48bn market value by 2026.But isn’t that an overly optimistic and linear path? In finding so, on this working paper, we describe some of Bayer and the industry’s main characteristics and challenges in the upcoming years, in light of a valuation model to estimate Bayer AG’s share price as of December 2022. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-12-17 2022-06-23T16:34:22Z 2022-01-13 2022-01-13T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/140596 TID:202972747 |
url |
http://hdl.handle.net/10362/140596 |
identifier_str_mv |
TID:202972747 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138095203876864 |